While the role of tumor-specific T cells in facilitating tumor regression has been demonstrated in advanced NSCLC, it is unknown how neoadjuvant PD-1 blockade affects the anti-tumor T cell repertoire and how these factors correlate with clinical outcome. Here, PDCD1 is linked to neoplasm.